The AIs included anlotinib, apatinib, and sunitinib. The ICIs included sintilimab, toripalimab, camrelizumab, and pembrolizumab. The treatment regimens are listed in Supplementary Table S1. Follow-up was routinely conducted every three months.
Free full text: Click here